Thursday, August 27, 2020

Fixx Pharmaceuticals Wants to Dominate Hemophilia Market With Gene Editing

SAN FRANCISCO, Aug. 27, 2020 /PRNewswire/ -- Fixx Pharmaceuticals Inc. is pleased to announce the launch of its biotechnology business operations in Las Vegas, Nevada and San Francisco, California. The company is focused on developing a cure for Hemophilia through the use of CRISPR gene...



from PR Newswire: https://ift.tt/3ljTK5b

No comments:

Post a Comment